ar101 - search results
If you're not happy with the results, please do another search
Aimmune to Begin Phase 2 Trials of Egg Allergy OIT Candidate
AR201 for Egg Allergy Phase 2 Initiation Planned for 2019.
Non-Profit Institute to Review Benefits of Commercial, Private Practice Immunotherapies for Peanut Allergy
An independent review of the value, costs and effectiveness of Viaskin Peanut, AR101, and private practice peanut OIT.
New Treatment to Protect People with Peanut Allergies Ready for FDA Review
"Two thirds of the people in the study were able to tolerate the equivalent of two peanuts per day after 9 to 12 months of treatment."
European Study Shows Significant Psychosocial Burden Associated with Peanut Allergy
Data discussed at EAACI 2018 reveal uncertainty, bullying and high levels of anxiety around food.
Peanut OIT Phase 3 Trial Results Show Therapy Effective for Ages 4-55
Aimmune plans to submit a Biologics License Application for AR101 to the FDA by the end of 2018.
Aimmune to Submit FDA Application for Peanut OIT Candidate by End 2018
If approved, AR101 could be offered as the first FDA approved OIT therapy for peanut allergy.
Results of Phase III Trial of Aimmune's Peanut OIT Therapy
After one year, 3/4 of patients ages 4-17 who received the therapy were able to consume a minimum of 300mg of peanut. Results for adults were less clear.
Aimmune, Regeneron and Sanofi Collaborate on Combination Peanut Therapy
More exciting news as pharma companies work to extend the effectiveness of their therapies in combination.
Aimmune Begins Patient Enrollment for Phase III Clinical Trial of Peanut Therapy
First of 440 patients enrolled in study of AR101.
Breakthrough Food Allergy Therapies and the Big Business Behind Them
What it means to be a breakthrough therapy, who is developing them, how they work, and the (big) business drivers behind them.
